FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2026863937> ?p ?o ?g. }

• W2026863937 endingPage "75" @default.
• W2026863937 startingPage "75" @default.
• W2026863937 abstract "Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents James Nuttall,1 Tammy Meyers,2 Brian Eley11Paediatric Infectious Diseases Unit, Red Cross War Memorial Children&#39;s Hospital and Department of Paediatrics and Child Health, University of Cape Town, Cape Town, South Africa; 2Department of Paediatrics, Chris Hani Baragwanath Hospital and Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South AfricaAbstract: Raltegravir (RAL) is the first integrase strand transfer inhibitor and has been shown to provide potent antiretroviral (ARV) activity against human immunodeficiency virus type 1 (HIV-1) in both ARV treatment-naïve and treatment-experienced individuals. Following initial US Food and Drug Administration (FDA) approval of RAL for treatment of HIV-1-infected adults in 2007, an ongoing pharmacokinetic, safety, and efficacy study in ARV-experienced children and adolescents led to extension of FDA approval to children and adolescents aged 2–18 years in 2011. Availability of chewable tablets for children aged 2–11 years is a significant advantage, and twice-daily dosing is recommended based on pharmacokinetic parameters. Granules for oral suspension in children 4 weeks to 2 years of age are currently under evaluation and clinical trials in neonates are imminent. Coadministration of RAL and the anti-tuberculosis drug rifampin (RIF) results in reduced RAL exposure. Evaluation of a double RAL dosing strategy in children requiring cotreatment with RIF is planned. RAL is generally well tolerated and has a good overall safety profile. Further data is required for children before RAL can be recommended in first-line ARV treatment regimens. RAL is also under investigation for use in preventing mother-to-child transmission both during pregnancy and in the HIV-exposed neonate. Currently, the main therapeutic role for RAL in children is for treatment failure and multi-drug resistant cases where the inclusion of RAL in combination with optimal background therapy has demonstrated successful outcomes. Increased availability of RAL and the introduction of second-generation integrase inhibitors are likely to further extend the utility of this class of ARV drugs.Keywords: antiretroviral therapy, integrase strand transfer inhibitor, raltegravir, HIV-1" @default.
• W2026863937 created "2016-06-24" @default.
• W2026863937 creator A5000854279 @default.
• W2026863937 creator A5069064367 @default.
• W2026863937 creator A5084792779 @default.
• W2026863937 date "2013-08-01" @default.
• W2026863937 modified "2023-09-24" @default.
• W2026863937 title "Clinical utility of raltegravir for the treatment of HIV infection in children and adolescents" @default.
• W2026863937 cites W1569413592 @default.
• W2026863937 cites W1965354305 @default.
• W2026863937 cites W1969518934 @default.
• W2026863937 cites W1974423393 @default.
• W2026863937 cites W1974671307 @default.
• W2026863937 cites W1990533335 @default.
• W2026863937 cites W1991819428 @default.
• W2026863937 cites W1994404131 @default.
• W2026863937 cites W1997048301 @default.
• W2026863937 cites W1997824449 @default.
• W2026863937 cites W1999502187 @default.
• W2026863937 cites W1999510588 @default.
• W2026863937 cites W2002108464 @default.
• W2026863937 cites W2007535230 @default.
• W2026863937 cites W2008250282 @default.
• W2026863937 cites W2011656694 @default.
• W2026863937 cites W2012050943 @default.
• W2026863937 cites W2015171620 @default.
• W2026863937 cites W2020610488 @default.
• W2026863937 cites W2023535692 @default.
• W2026863937 cites W2025481927 @default.
• W2026863937 cites W2035858595 @default.
• W2026863937 cites W2040468325 @default.
• W2026863937 cites W2044233832 @default.
• W2026863937 cites W2049140789 @default.
• W2026863937 cites W2050388518 @default.
• W2026863937 cites W2053125329 @default.
• W2026863937 cites W2056596520 @default.
• W2026863937 cites W2060438300 @default.
• W2026863937 cites W2061913620 @default.
• W2026863937 cites W2062803628 @default.
• W2026863937 cites W2075531822 @default.
• W2026863937 cites W2077432042 @default.
• W2026863937 cites W2087098674 @default.
• W2026863937 cites W2087445857 @default.
• W2026863937 cites W2088811688 @default.
• W2026863937 cites W2104479242 @default.
• W2026863937 cites W2107574856 @default.
• W2026863937 cites W2108622585 @default.
• W2026863937 cites W2109360985 @default.
• W2026863937 cites W2110265421 @default.
• W2026863937 cites W2110488501 @default.
• W2026863937 cites W2110945650 @default.
• W2026863937 cites W2114822477 @default.
• W2026863937 cites W2115179084 @default.
• W2026863937 cites W2118636292 @default.
• W2026863937 cites W2122986037 @default.
• W2026863937 cites W2123055341 @default.
• W2026863937 cites W2131867774 @default.
• W2026863937 cites W2133362267 @default.
• W2026863937 cites W2135417699 @default.
• W2026863937 cites W2137994859 @default.
• W2026863937 cites W2139240980 @default.
• W2026863937 cites W2143870105 @default.
• W2026863937 cites W2147210767 @default.
• W2026863937 cites W2148544227 @default.
• W2026863937 cites W2148750104 @default.
• W2026863937 cites W2150226114 @default.
• W2026863937 cites W2152991448 @default.
• W2026863937 cites W2159106465 @default.
• W2026863937 cites W2159328065 @default.
• W2026863937 cites W2160872860 @default.
• W2026863937 cites W2161167378 @default.
• W2026863937 cites W2161993838 @default.
• W2026863937 cites W2162749908 @default.
• W2026863937 cites W2163866093 @default.
• W2026863937 cites W2165447838 @default.
• W2026863937 cites W2166406123 @default.
• W2026863937 cites W2169218167 @default.
• W2026863937 cites W2170162787 @default.
• W2026863937 cites W2171711893 @default.
• W2026863937 cites W2312235623 @default.
• W2026863937 cites W2331103572 @default.
• W2026863937 cites W2470303801 @default.
• W2026863937 cites W2083147325 @default.
• W2026863937 cites W2188664326 @default.
• W2026863937 doi "https://doi.org/10.2147/phmt.s34925" @default.
• W2026863937 hasPublicationYear "2013" @default.
• W2026863937 type Work @default.
• W2026863937 sameAs 2026863937 @default.
• W2026863937 citedByCount "0" @default.
• W2026863937 crossrefType "journal-article" @default.
• W2026863937 hasAuthorship W2026863937A5000854279 @default.
• W2026863937 hasAuthorship W2026863937A5069064367 @default.
• W2026863937 hasAuthorship W2026863937A5084792779 @default.
• W2026863937 hasBestOaLocation W20268639371 @default.
• W2026863937 hasConcept C126322002 @default.
• W2026863937 hasConcept C142462285 @default.
• W2026863937 hasConcept C187212893 @default.
• W2026863937 hasConcept C2777288759 @default.

• next